Product Name:	Anti-Mouse PD-L2 (CD273) In Vivo Antibody - Ultra Low Endotoxin
Product Code:	IVMB0115
Size:	1mg, 5mg, 25mg, 50mg, 100mg
Clone:	3.2.B8
Protein:	PD-L2
Product Type:	Monoclonal Antibody
Synonyms:	B7-DC, CD273, PDL2, B7DC, Clone 3.2
Isotype:	Mouse IgG1
Reactivity:	Mouse/Human
Immunogen:	Made in PD-L2 knockout mouse fusion partner X63-Ag8.653 myeloma cells
Applications:	B, FC, WB
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥98% monomer by analytical SEC >95% by SDS Page
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:	B, FC, WB
Recommended Usage:	WB For Western blot analysis at a concentration of 1.0-2.0 µg/ml when used in conjunction with compatible secondary reagents Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Reactivity:	Mouse/Human

Host Species:	Mouse
Specificity:	Clone 3.2.B8 recognizes an epitope on mouse/human PD-L2 and has been shown to bind to both mouse and human PD-L2 equally well
Antigen Distribution:	PD-L2 is expressed on dendritic cells, liver, few transformed cell lines, and a subset of macrophages.
Immunogen:	Made in PD-L2 knockout mouse fusion partner X63-Ag8.653 myeloma cells
Concentration:	≥ 5.0 mg/ml
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥98% monomer by analytical SEC >95% by SDS Page
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Technical Datasheet:	View
Protein:	PD-L2
Function:	Binds to PD-1 and alternative receptor
Ligand/Receptor:	PD-1
Research Area:	Costimulatory Molecules, Immunology